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Increased susceptibility to erythrocyte C5b-9 deposition and
complement-mediated lysis in chronic renal failure
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to complement-mediated erythrocyte injury may contribute toIncreased susceptibility to erythrocyte C5b-9 deposition and
the anemia of chronic renal disease.complement-mediated lysis in chronic renal failure.
Background. Decreased red blood cell survival contributes
to the anemia of chronic renal failure patients. Because patients
on chronic dialysis therapy are frequently exposed to excessive
Progressive chronic renal failure results in adverse he-complement activation, we investigated the susceptibility of
matologic effects, including the development of anemiathis patient population to erythrocyte C5b-9 deposition, com-
plement-mediated lysis, and ghost formation. [1, 2]. The principal cause of the anemia of chronic renal
Methods. We developed a flow cytometric assay using anti- disease is a decrease in erythropoietin production caused
bodies to both glycophorin and the C5b-9 complex to detect by the loss of functional renal tissue [3]. In addition,C5b-9 deposition on intact erythrocytes and erythrocyte ghosts.
shortened erythrocyte survival, the presence of uremicSerum C5b-9 levels and C5b-9 deposition on erythrocyte ghosts
inhibitors of erythropoiesis, excessive bleeding, and ironwere measured by enzyme-linked immunosorbent assay.
Results. A significant increase in C5b-9 deposition on intact deficiency have all been proposed as factors contributing
erythrocytes was demonstrated in patients with advanced to the anemia of chronic renal failure [4–6]. Although
chronic renal failure (2.2 6 0.5%) and in patients on chronic
the anemia of chronic renal failure stabilizes in patientsmaintenance hemodialysis (2.3 6 0.4%) compared with normal
initiated on peritoneal dialysis, patients initiated onvolunteers (0.9 6 0.1%, P 5 0.005 vs. chronic renal failure,
P , 0.001 vs. chronic hemodialysis patients). There was also chronic maintenance hemodialysis generally have a fur-
a significantly higher percentage of C5b-9–positive erythrocyte ther reduction of their hematocrit [7] and require phar-
ghosts in patients with advanced chronic renal failure (20.6 6 macologic doses of exogenous erythropoietin to maintain5%) and in chronic hemodialysis patients (15.5 6 3.1%) com-
a hematocrit of approximately 30%. Erythrocyte survivalpared with normal controls (2.6 6 0.9%, P # 0.001 vs. advanced
chronic renal failure and chronic hemodialysis patients). Treat- in patients with renal failure is markedly shortened and,
ment of erythrocyte preparations with cobra venom factor, in many studies, approaches half of the survival span
which activates the complement cascade, resulted in dramatic of normal individuals [3, 8–14]. Most isotopic studies
increases in the percentages of C5b-9–positive erythrocyte
demonstrate the presence of mild hemolysis, the etiologyghosts in patients with chronic renal failure (49.9 6 6.9%) and
of which has not been defined [3].in chronic hemodialysis patients (45.0 6 4.2%) compared with
normal volunteers (22.3 6 2.7%, P , 0.001 vs. chronic renal In addition to decreased erythrocyte survival, a variety
failure and chronic hemodialysis patients). Erythrocyte mem- of morphologic and functional erythrocyte abnormalities
brane expression of the complement regulatory proteins CD59
has been reported in patients with chronic renal failureand CD55 did not significantly differ between normal controls
on hemodialysis. These include a high percentage ofand hemodialysis patients. Plasma C5b-9 levels after cobra
venom factor stimulation were higher in chronic renal failure anicytosis [15], deficiencies of the hexose monophos-
patients (538 mg/ml) compared with normal controls (345 mg/ phate shunt pathway [7, 8], reduced deformability of the
ml, P , 0.001). erythrocyte membrane, and reduced erythrocyte diffu-Conclusions. Patients with chronic renal failure and on he-
sion coefficients for small molecular weight substancesmodialysis therapy are susceptible to erythrocyte C5b-9 deposi-
such as urea or creatinine [16]. Although considerabletion with subsequent lysis and ghost formation. Susceptibility
data describe structural abnormalities of the erythrocyte
membrane in patients on chronic hemodialysis, to date,Key words: anemia, complement-mediated erythrocyte injury, red
blood cells, dialysis, uremia. there has been little investigation of the mechanisms of
these abnormalities.
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18]. Additionally, patients on chronic hemodialysis are Subjects
frequently exposed to increased complement activation Twenty patients on chronic maintenance hemodialy-
as a result of inflammatory processes, including the con- sis, 20 patients with chronic renal failure and creatinine
tact of blood with dialysis membranes [19, 20]. The termi- greater than 5 mg/dl not receiving dialysis therapy, and
nal sequence of complement activation is initiated after 20 volunteers with normal kidney function were asked
cleavage of C5 and leads to assembly of the membrane to participate. The etiology of renal failure in patients
attack complex (C5b-9) on target cell membranes [21]. not on dialysis was diabetes mellitus (seven patients),
This creates a transmembrane pore that is functionally hypertension (five patients), glomerular disease (six pa-
expressed by increased ion permeability of a cell mem- tients), polycystic kidney disease (one patient), and Al-
brane, leading to osmotic swelling and lysis of the target port’s disease (one patient). The etiology of renal failure
in patients on hemodialysis was hypertension (nine pa-cell with subsequent ghost formation. Fluid phase gener-
tients), diabetes mellitus (three patients), glomerular dis-ation of the terminal complement complex occurs during
ease (two patients), polycystic kidney disease (one pa-hemodialysis and has been proposed as a measure of
tient), chronic pyelonephritis (two patients), interstitialmembrane biocompatibility [22–25].
nephritis (one patient), and unknown (two patients). AllNucleated cells and platelets have evolved a variety
patients on chronic hemodialysis therapy were dialyzedof mechanisms to protect against complement membrane
with high-flux polysulfone membranes (F-80; Fresenius,attack complex-mediated lysis specifically by endocytosis
Germany) prior to entry into the study. Blood was col-or by an exocytic process of blebbing vesicles [26–29].
lected into Vacutainer tubes containing either ethylene-On the other hand, erythrocytes are much more suscepti-
diaminetetraacetic acid (EDTA) or heparin as an antico-ble to complement-mediated lysis [30, 31]. Plasma mem-
agulant for plasma studies or tubes with no anticoagulantbranes are protected by proteins such as CD59 (pro-
for serum studies. Blood samples from hemodialysis pa-tectin), which specifically prevents the assembly of the
tients were obtained after needles were inserted but be-membrane attack complex, as well as proteins such as
fore heparin bolus was administered prior to dialysis.decay accelerating factor [32, 33], which inhibits activa-
Blood samples were kept at 48C until prepared for assay,tion of the complement cascade at the level of formation
which, in all cases, was within 60 minutes of bloodof the C3 and C5 convertase [32–34].
drawing.Because patients with renal failure are frequently ex-
posed to complement activation and complement activa- Preparation of 1% hematocrit for flow cytometry
tion could lead to erythrocyte membrane injury and
Blood samples with no anticoagulant were allowed toghost formation, we hypothesized that complement acti-
clot and were centrifuged at 1,800 3 g for 10 minutes, andvation could contribute to the structural and functional
serum was collected. Paired blood samples containingerythrocyte changes seen in patients in renal failure. We
anticoagulants were centrifuged at 150 3 g for five min-
therefore investigated erythrocyte susceptibility to C5b-9
utes, after which the plasma and leukocyte layers were
deposition and lysis in patients with chronic renal failure
removed and discarded. A 10 ml aliquot of the remaining
and in hemodialysis patients compared with normal con- concentrated red cells was added to 1 ml autologous
trols. serum, resulting in a red cell concentration of 1%.
Complement activationMETHODS
To activate complement in vitro for experiments usingReagents
flow cytometry, 1.3 units of cobra venom factor were
Cobra venom factor and SC5b-9 enzyme-linked immu- added to 1 ml of 1% hematocrit samples and were incu-
nosorbent assay (ELISA) kits were obtained from Qui- bated for two hours at 378C. Control samples consisted
del Corporation (San Diego, CA, USA). Antibody to of 1% hematocrit samples, with EDTA added to prevent
C5b-9 (terminal complement complex), antibody to gly- complement activation, that were held on ice for two
cophorin A conjugated to fluorescein isothiocyanate, and hours. To activate complement in vitro for experiments
antibody to mouse immunoglobulins conjugated to phy- using ELISA, 10 units of cobra venom factor were added
coerythrin came from Dako Corporation (Carpinteria, to 1 ml whole blood with heparin and were incubated
CA, USA). Antibody to CD59 conjugated to phycoer- two hours at 378C. Controls consisted of paired samples
ythrin and antibody to decay accelerating factor (CD55) with EDTA added that were stored on ice for two hours.
conjugated to fluorescein isothiocyanate were purchased
Preparation of red cell ghosts for ELISAfrom Research Diagnostics Inc. (Flanders, NJ, USA) and
Wako Pure Chemical Industrial Ltd. (Osaka, Japan), Red cell ghosts were prepared following the method of
Salama et al [35]. Briefly, after incubation with or withoutrespectively.
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cobra venom factor, whole blood samples were centri-
fuged at 1,800 3 g for 20 minutes, and plasma was obtained.
Plasma was then centrifuged at 14,000 3 g for five min-
utes, and the supernatant was frozen for later testing for
SC5b-9 in plasma, using ELISA techniques. Pellets from
the plasma sample were washed three times with phos-
phate-buffered saline (PBS)-0.2% BSA with 14,000 3 g
centrifugation for five minutes and then solubilized with
Triton X-100 and again centrifuged at 14,000 3 g for
five minutes. The supernatant was frozen for later testing
as ghosts in the SC5b-9 ELISA assay.
Fig. 1. Identification of C5b-9 deposition on intact erythrocytes by flow
cytometry. #P , 0.01 vs. normal controls; *P , 0.01 vs. samples withoutFlow cytometry analysis
the addition of cobra venom factor (CVF). Symbols are: (h) no CVF;
To determine whether patients with advanced chronic ( ) CVF.
renal failure or patients on chronic hemodialysis therapy
have increased erythrocyte susceptibility to complement
C5b-9 deposition, we developed a flow cytometric assay
variance was applied, followed by the Student t-test forto measure C5b-9 deposition on intact erythrocytes. This
unpaired samples assuming equal or unequal variance,assay uses dual color immunofluorescence with fluores-
as determined by the F-test.cein isothiocyanate and phycoerythrin-conjugated anti-
bodies to detect the presence of both glycophorin and
C5b-9 complex on erythrocyte cell membranes. One hun- RESULTS
dred microliter aliquots of 1% hematocrit samples were
Erythrocyte C5b-9 depositionfixed by incubation with an equal volume of 2% para-
In normal volunteers, “background” C5b-9 could beformaldehyde at 48C for one hour, followed by washing
detected on 0.9 6 0.1% of intact erythrocytes in thiswith PBS. Samples were incubated as appropriate either
assay system (Fig. 1). This background C5b-9 depositiondirectly with fluorescein-conjugated antibodies (glyco-
on intact erythrocytes was twice as high in patients withphorin A, CD55), phycoerythrin-conjugated antibodies
advanced chronic renal failure (2.2 6 0.5%, P 5 0.005(CD59), or with an antibody to C5b-9 followed by phy-
vs. normal volunteers) and in patients on chronic mainte-coerythrin-conjugated goat antimouse antibodies at 48C
nance hemodialysis (2.3 6 0.4%, P 5 0.0003 vs. normalfor 20 minutes and were then washed with PBS. Follow-
volunteers). Incubation of preparations of intact erythro-ing the final wash, 1 ml PBS was added per tube, and
cytes of the same patients in autologous serum with 1.3samples were analyzed on a FACSCAN (Becton Dickin-
units/ml of cobra venom factor resulted in a dramaticson, Mountain View, CA, USA).
increase in C5b-9 deposition on intact erythrocytes in
ELISA for SC5b-9 normal volunteers (34.2 6 3.0%, P , 0.0001 vs. without
cobra venom factor), in patients with advanced chronicPreparations of both plasma and solubilized erythro-
renal failure (34.2 6 5.2%, P 5 0.00001 vs. without cobracyte ghosts were analyzed for SC5b-9 content. Plasma
venom factor), and in chronic hemodialysis patientssamples were diluted to fall within the standard curve
(35.1 6 2.3%, P , 0.0001 vs. without cobra venom fac-of the assay. Erythrocyte ghost preparations were diluted
tor). There were no significant differences in the levelto a 300 ml volume with specimen diluent to yield enough
of C5b-9 deposition on intact erythrocytes after cobravolume for testing. Samples were assayed for the SC5b-9
venom factor stimulation between the two patientcomplex using an enzyme immunoassay (Quidel).
groups. Electron microscopy was also performed on
Lactate dehydrogenase complement activated erythrocyte preparations and
demonstrated erythrocyte membrane blebbing charac-Plasma lactate dehydrogenase (LDH) levels were
teristic of C5b-9–mediated membrane attack complexmeasured using a Hitachi 747 Analyzer.
(Fig. 2).
Statistics
Erythrocyte ghost formation and C5b-9 depositionAn analysis of variance was performed, followed by
In addition to detecting C5b-9 deposition on intacta two-tailed Student t-test. For comparison of untreated
erythrocytes, we used both a flow cytometric assay and ansamples to cobra venom factor-treated samples, the Stu-
ELISA assay to detect C5b-9 deposition on erythrocytedent t-test for paired samples was applied. For compari-
ghosts. Using flow cytometry, erythrocyte ghosts wereson of samples from normal volunteers, chronic renal
failure patients, and hemodialysis patients, the F-test for detected using a combination of forward angle light scat-
Fig. 2. Electron micrographs demonstrating erythrocyte membrane blebbing and ghost formation after addition of cobra venom factor. Panel B
represents further magnification of A.
Himmelfarb et al: Erythrocyte C5b-9 deposition in renal failure 663
Fig. 3. Identification of C5b-9 deposition on erythrocyte ghosts using
flow cytometry. #P , 0.01 vs. normal volunteers; *P , 0.01 vs. samples Fig. 4. Identification of C5b-9 deposition on erythrocyte ghosts by
without the addition of cobra venom factor. Symbols are: (h) no CVF; ELISA. #P , 0.01 vs. normal volunteers; *P , 0.01 vs. samples without
( ) CVF. cobra venom factor. Symbols are: (h) no CVF; ( ) CVF.
ter and antibodies to glycophorin to identify erythrocyte
lineage specifically (Fig. 3). In the erythrocyte prep-
arations from normal volunteers, there was minimally
detectable C5b-9 deposition on identified ghosts (2.6 6
0.9%). In contrast, there was a significantly higher per-
centage of erythrocyte ghosts with detectable C5b-9
deposition in both patients with advanced chronic renal
failure (20.6 6 5%, P 5 0.001 vs. normal controls) and
patients on chronic maintenance hemodialysis (15.5 6
3.1%, P 5 0.0003 vs. normal controls).
Treatment of erythrocyte preparations from normal
volunteers with cobra venom factor resulted in a 10-fold
increase in the percentage of erythrocyte ghosts with
detectable C5b-9 deposition (22.3 6 2.7%, P , 0.00001). Fig. 5. Erythrocyte surface protectin (CD59) and decay accelerating
factor (CD55), measured by flow cytometry. Symbols are: (h) no dial-There was an even greater augmentation of detectable
ysis; ( ) dialysis.C5b-9 on erythrocyte ghosts after cobra venom factor
stimulation in patients with advanced chronic renal fail-
ure (49.9 6 6.9%, P 5 0.0009 vs. samples without addi-
tion of cobra venom factor, P , 0.01 vs. cobra venom 0.001 vs. without cobra venom factor). Patients on
chronic maintenance hemodialysis also had 6.6 6 2.6 ng/factor-treated samples from normal volunteers) and
from chronic hemodialysis patients (45.0 6 4.2%, P , ml C5b-9–positive ghosts detected by ELISA, which was
not significantly different from either normal volunteers0.0001 vs. samples without addition of cobra venom fac-
tor, P , 0.0001 vs. cobra venom factor-treated samples or patients with advanced chronic renal failure. The addi-
tion of cobra venom factor resulted in a further augmen-from normal volunteers).
To confirm results obtained with the flow cytometric tation of detectable C5b-9–positive ghosts (108 6 14,
P , 0.001 vs. samples without cobra venom factor).assay, we also employed an ELISA assay to detect
C5b-9–positive erythrocyte ghosts in patients with ad-
Erythrocyte complement receptorsvanced chronic renal failure, chronic hemodialysis pa-
tients, and normal volunteers. Normal volunteers had Increased susceptibility to erythrocyte C5b-9 deposi-
tion and subsequent ghost formation in patients withrelatively low levels of detectable C5b-9–positive ghosts
(3.4 6 1.5 ng/ml; Fig. 4). The addition of cobra venom chronic renal failure and patients on chronic hemodialy-
sis could be due to alterations in erythrocyte complementfactor to these sample preparations increased the level
of C5b-9–positive ghosts to 72.0 6 12 ng/ml (P , 0.001 vs. regulatory proteins. We examined erythrocyte mem-
brane expression of both CD59 (protectin) and CD55without cobra venom factor). In patients with advanced
chronic renal failure, the level of detectable C5b-9– (decay-accelerating factor) using flow cytometry (Fig. 5).
Erythrocyte membrane CD59 expression did not varypositive ghosts in erythrocyte preparations was 17 6 4.7
ng/ml (P 5 0.01 vs. normal volunteers) and increased to between normal controls (55 6 0.6 mean fluorescence
channels), and patients on chronic maintenance hemodi-79 6 11 ng/ml after cobra venom factor stimulation (P ,
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Fig.7. Intradialytic increases in LDH levels. *P , 0.05 compared withFig. 6. SC5b-9 levels measured by ELISA after cobra venom factor
predialysis. Symbols are: (j) 15 min; ( ) 60 min; (h).stimulation. *P , 0.00 vs. normal volunteers.
alysis (54 6 0.6 mean fluorescence channels). Similarly, In contrast, there were no significant changes in LDH
erythrocyte membrane expression of CD55 did not vary levels throughout the dialysis procedure in patients dia-
between normal controls (6.6 6 0.3 mean fluorescence lyzed with the polysulfone membranes. These studies
channels) or patients on chronic dialysis therapy (7.3 6 demonstrate that complement activation may contribute
0.3 mean fluorescence channels). to hemolysis in vivo in this patient population.
Plasma C5b-9
DISCUSSIONIncreased susceptibility of erythrocytes to C5b-9 depo-
sition could be due to either more vigorous complement We have demonstrated that in patients with advanced
chronic renal failure and patients on chronic dialysis,activation or to changes in the erythrocyte structure in
patients with chronic renal failure and in patients on there is increased deposition of the C5b-9 complex on
both intact erythrocytes and erythrocyte ghosts. The in-chronic dialysis therapy. We therefore measured plasma
C5b-9 levels before and after cobra venom factor stimu- creased susceptibility of uremic erythrocytes to mem-
brane attack complex deposition and lysis does not ap-lation. Baseline plasma C5b-9 levels were low in all
groups (252 6 22 ng/ml in normal controls, 189 6 41 pear to be due entirely to an increase in the level of
plasma C5b-9 formation nor to changes in erythrocyte-ng/ml in chronic renal failure patients, and 127 6 19
ng/ml in hemodialysis patients). After stimulation with associated complement regulatory proteins such as pro-
tectin (CD59) or decay-accelerating factor (CD55).cobra venom factor, there was a significant increase in
plasma C5b-9 production in chronic renal failure patients Until recently, it has been generally accepted that
erythrocytes will be lysed if a single C5b-9 channel is(538 6 44 mg/ml, P , 0.001) but not in hemodialysis
patients (430 6 38 mg/ml, P 5 0.07) compared with formed in the plasma membrane (the “one hit” theory
of complement mediated lysis) [30]. This concept hasnormal controls (345 6 23 mg/ml; Fig. 6).
recently been challenged by studies demonstrating that
Intradialytic changes in LDH human erythrocytes can survive sublytic amounts of the
formation of the membrane attack complex by efficientlyTo investigate whether altered susceptibility to C5b-9
erythrocyte deposition and subsequent ghost formation taking up sodium until lysis can be prevented by mem-
brane vesiculation [36, 37]. It has also recently beenin patients on chronic hemodialysis might have in vivo
significance, we measured intradialytic levels of LDH as shown that human erythrocytes, as opposed to sheep
erythrocytes, can eliminate membrane attack complexa marker of hemolysis (Fig. 7). Ten patients on chronic
dialysis therapy were each dialyzed on successive occa- channels by vesiculation in a process similar to nucleated
cells [29]. The results in this article, which demonstratesions with an unmodified cellulosic membrane (which
vigorously activates the alternative pathway of comple- nonlytic binding of C5b-9 complexes to intact erythro-
cytes, confirm the recent findings that human erythro-ment) and with a polysulfone membrane (which mini-
mally activates the alternative pathway of complement). cytes may survive formation of the membrane attack
complex. The demonstration of erythrocyte membraneIn patients dialyzed with unmodified cellulosic mem-
branes, there was a significant increase in LDH at both vesiculation and bleb formation by electron microscopy
after complement activation provides further evidence60 minutes (62 1 21 m/liter increase, P , 0.05) and at
the end of dialysis (98 1 28 m/liter increase, P , 0.05). to support this concept.
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The finding of increased susceptibility of chronic he- polysulfone membranes may partially remove factor D
modialysis patients and patients with advanced chronic (molecular weight approximately 34,000), thereby ex-
renal failure to erythrocyte C5b-9 deposition and com- plaining the difference in plasma C5b-9 generation be-
plement-mediated lysis has potential clinical implica- tween patients on dialysis and those with chronic renal
tions. Although the major cause of the anemia of chronic failure not on dialysis in this study. However, higher
renal disease is related to deficient erythropoietin pro- levels of plasma production of C5b-9 after cobra venom
duction, erythrocyte survival times are shortened in ure- factor stimulation are unlikely to account for all of the
mia and may partly account for the anemia of chronic changes in C5b-9 deposition and ghost formation in both
renal failure and for the need for pharmacologic doses patients with chronic renal failure and patients on
of erythropoietin for patients on hemodialysis [3, 8–14]. chronic hemodialysis therapy observed in this study.
Thus, susceptibility to complement activation and short- This study does not clearly demonstrate a mechanism
ened erythrocyte half-life could affect erythropoietin for increased uremic erythrocyte susceptibility to com-
(EPO) dosing requirements in chronic renal failure. plement deposition. Both patients and controls had simi-
It is well known that patients on chronic maintenance lar levels of erythrocyte expression of complement regu-
hemodialysis are frequently and repetitively exposed to latory proteins. Although CD59 levels were similar
high levels of complement activation resulting in mem- between the patient groups, it is possible that proteins
brane attack complex formation, particularly when pa- or protein fragments that are retained with renal failure
tients are dialyzed with unmodified cellulosic membranes could bind to and inactivate CD59, thereby reducing
[22–25]. Even relatively biocompatible membranes are efficacy in binding to C8 and/or C9 in the nascent mem-
often associated with vigorous complement activation at brane attack complex and interfering with C9 membrane
the luminal surface of the fibers, although to a lesser insertion and polymerization. Tomlinson, Whitlow and
degree than seen with the use of bioincompatible mem- Nussenzweig have recently demonstrated that synthetic
branes [38]. Our studies also indicate that patients with peptides derived from complement protein C9 can bind
chronic renal failure have evidence of increased comple- to CD59 and thereby enhance lysis of human erythro-
ment activation even prior to their initiation on dialysis cytes by C5b-9 [39]. However, to our knowledge, no such
therapy, suggesting that uremia per se may cause higher naturally occurring peptides have been identified in vivo
levels of complement activation. Thus, the combination in either normal individuals or in patients with renal
of increased erythrocyte susceptibility to C5b-9 deposi- disease. Alternatively, erythrocytes from patients with
tion in uremia, coupled with increased exposure to com- chronic renal failure may differ from those in normal
plement activation, could contribute to functional and volunteers because of increased oxidative modification
structural erythrocyte membrane dysfunction and short- or other biochemical changes in the plasma membrane
ened erythrocyte survival in uremia. The finding in this that might increase the likelihood of binding of C5b or
study that the use of complement-activating dialysis other components of the terminal complement pathways
membranes leads to increased hemolysis, as evidenced [40, 41]. These and other explanations of the observed
by increased LDH levels, further demonstrates the po- increased susceptibility of uremic erythrocytes to com-
tential impact of these mechanisms on decreased eryth- plement deposition remain speculative at our present
rocyte survival in this patient population. However, cur- level of understanding.
rently, the relationship between altered susceptibility to In summary, we have demonstrated that erythrocytes
complement-mediated erythrocyte lysis and shortened from patients with chronic renal failure and patients on
erythrocyte survival in chronic hemodialysis patients has chronic hemodialysis therapy have increased susceptibil-
not been documented. ity to C5b-9 deposition with subsequent erythrocyte
In this study, we also noted that the plasma production
ghost formation. Increased uremic erythrocyte suscepti-
of C5b-9 after cobra venom factor stimulation was higher
bility to complement-mediated lysis was not associatedin patients with chronic renal failure than in either normal
with major differences in levels of erythrocyte comple-controls or patients on chronic hemodialysis therapy. Al-
ment receptor proteins or plasma C5b-9 production. In-though not directly demonstrated in this study, increased
creased susceptibility to complement-mediated lysisalternative pathway of complement activation in patients
could contribute to shortened erythrocyte survival inwith chronic renal failure may be due to accumulation
uremia and to the anemia of chronic renal disease.of factor D in uremia [17, 18]. Complement factor D
participates in the formation of the alternative pathway
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